Loading... Please wait...

Our Newsletter

AZD8055 | mTOR inhibitor

  • AZD8055.jpg
  • AZD8055, 400x400px, png
Catalog #:

Product Description

AZD8055 is a potent and orally bioavailable ATP-competitive inhibitor of mTOR kinase with an IC50 of 0.8 nM. It inhibits both mTORC1 and mTORC2. AZD8055 shows excellent selectivity (1,000-fold) against all class I PI3K isoforms and other members of the PI3K-like kinase family. Furthermore, AZD8055 showed no significant activity against a panel of 260 kinases at concentrations up to 10 µM [1].

The serine/threonine kinase mTOR is crucial for cell growth and proliferation. It regulates cap-dependent translation through the mTORC1 complex and Akt activation through the mTORC2 complex. AZD8055 inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as the phosphorylation of the mTORC2 substrate AKT. AZD8055 potently inhibits proliferation, induces autophagy and apoptosis in different cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT and results in significant tumor growth inhibition and/or regression in xenografts representing a broad range of tumor types [1-4].

Technical information:

Chemical Formula:   C25H31N5O4
CAS #:   1009298-09-2
Molecular Weight:   465.54
Purity:   > 98%
Appearance:   White
Chemical Name:   (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
Solubility:   Up to 22 mM in DMSO
Synonyms:   AZD8055, AZD-8055

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010. 70(1):288-98. Pubmed ID: 20028854
2. Sini P, et al. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy. 2010. 6(4). Pubmed ID: 20364113
3. Willems L, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. . Leukemia. 2012. 26(6):1195-202. Pubmed ID: 22143671
4. Naing A,et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012. 107(7):1093-9. Pubmed ID: 22935583

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the AZD8055 | mTOR inhibitor to your wish list.

You Recently Viewed...